Ninlaro (ixazomib)

€6,894.25
In stock
SKU
Ninlaro (ixazomib)

 Ninlaro (ixazomib) is a medication used for the treatment of multiple myeloma.

How to buy Ninlaro (ixazomib): You can order Ninlaro (ixazomib) from TheSocialMedwork if the drug has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Oncology Multiple Myeloma
Marketing Authorisation Holder Takeda Pharma A/S
Mode of Action Proteasome inhibitor (chemotherapy)
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Package 3 Capsules

What is Ninlaro (ixazomib) for?

Ninlaro (Ixazomib) is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

How does Ninlaro (ixazomib) work?

Ninlaro (ixazomib) targets and reversibly inhibits the proteasome enzyme complex within the cell. Proteasome is part of the cellular machinery, and among its functions, it regulates cellular division and survival. By interfering with proteasome’s function, ixazomib can lead to apoptosis (cell death)2.

Ixazomib demonstrated in vitro cytotoxicity against myeloma cells from patients who had relapsed after multiple prior therapies, including bortezomib, lenalidomide, and dexamethasone. The combination of ixazomib and lenalidomide demonstrated synergistic cytotoxic effects in multiple myeloma cell lines1.

Is Ninlaro (ixazomib) approved?

Ixazomib was approved or the treatment of patients with multiple myeloma who have received at least one prior therapy1 by:

  • Food and Drug Administration (FDA) (USA) September 20, 2015

  • Therapeutic Goods Administration (TGA) (AUS) November 15, 2016

  • European Medicines Agency (EMA) (EUR) EMA November 24, 20165

How do I take Ninlaro (ixazomib)?

The standard dosage is:

  • 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle

  • Dose should be taken at least one hour before or at least two hours after food

  • The dose may be reduced to 3 mg and to 2.3 mg in patients with moderately or severely reduced liver function and patients with severely reduced kidney function

Complete information about ixazomib dosage and administration can be found in the resources section.

Consult your treating doctor for personalised dosing.


More Information
Working ingredient ixazomib
Shipping method Controlled room temperature (temperature controlled)
Package 3
Therapeutic Area Oncology
Oncology Multiple Myeloma
Indication Relapsed multiple myeloma
Administration Oral
Mode of Action Proteasome inhibitor (chemotherapy)
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Takeda Pharma A/S
HS Code 29319080
CAS Number 1072833-77-2

The approval was based on an improvement in progression-free survival (PFS) in a multicentre, randomised, double-blind, placebo-controlled trial enrolling 722 patients with multiple myeloma who had received 1 to 3 prior lines of therapy. Patients were randomised in a 1:1 ratio to receive either a combination of ixazomib, lenalidomide and dexamethasone (n = 360) or the combination of placebo, lenalidomide and dexamethasone (n = 362). Patients continued treatment until disease progression or unacceptable toxicity. The trial showed a statistically significant improvement in PFS. The median PFS on the combination arm of ixazomib, lenalidomide and dexamethasone was 20.6 months (95% CI: 17.0, NE) compared to a median PFS of 14.7 months (95% CI: 12.9, 17.6) on the combination arm of placebo, lenalidomide and dexamethasone (PFS HR 0.74, 95% CI: 0.59, 0.94; p value=0.012)4.

Common side effects of Ninlaro (ixazomib)

The more common (>20%) adverse reactions associated with an increased rate on the ixazomib combination arm compared to the placebo combination arm were4:

  • diarrhoea
  • constipation
  • thrombocytopenia
  • peripheral neuropathy
  • nausea
  • peripheral edema
  • vomiting
  • back pain.

1. Summary of Product Characteristics: Ninlaro (ixazomib) [PDF]
    Takeda Pharmaceuticals America, Inc., FDA, Nov 2015

2. FDA archive. Ixazomib
    FDA archive, cited Aug 2016

3. Human Medicines: Ninlaro (ixazomib)
    EMA, cited April 2017

4. Summary of Product Characteristics: Ninlaro (ixazomib) [PDF]
    Takeda Pharmaceuticals, EMA, Nov 2016

5. Ninlaro (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma
    Takeda Press Release, Nov 2016

6. TGA Public Summary: Ninlaro (ixazomib)
    TGA, Nov 2016

Shipping Type Cold Chain
Shipping method Controlled room temperature (temperature controlled)
Dynamic Weight No
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

How can we help you?

We're ready to answer any question!

Our Support team is available between
9:00–18:00 Central European Time, Monday to Friday.

 

Don't speak English? We also speak
Afrikaans, Armenian, Bosnian, Bulgarian, Dutch, French, German, Italian, Lithuanian, Mandarin, Polish, Portuguese, Russian, Serbian, Slovenian, Spanish and Turkish

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 


Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.